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Abstract: Objective: To compare the performance of anti-granulocyte scintigraphy with those of
widely used prognostic indices (such as DAS28, anti-CCP, early MRI imaging).
Methods: Twenty-five patients with early arthritis were enrolled into the study.
Following the review of clinical data and the evaluation of disease activity, we
performed MRI imaging of the hands, anti-granulocyte scintigraphy, and determined
anti-CCP positivity.  The relationship between the changes of MRI scores and the
above prognostic factors were analyzed statistically.
Results:  At baseline, values were as follows: DAS28 3.86±1.19, CRI 0.15±0.12, MRI
erosions and synovitis scores 25.11±12.82 and 4.32±4.02 (respectively), the ratio of
anti-CCP positivity was 7/12 (58%). After the follow-up period of 13.6±2.52 months,
erosion and synovitis scores were 43.11±22.23, and 5.32±6.16, respectively (p=0,001
and p=0,015). The occurrence of new erosions was correlated with baseline erosion
score (k=0.523, p=0.022) and anti-CCP positivity (p=0.021).The relationship between
CRI and baseline synovitis score was strong (=0.518, p=0.023), whereas it was weak
only between the former and baseline erosion score (=0.402, p=0.08).
Conclusion: As shown by this study, potential markers for predicting subsequent
destructiveness in early RA include MRI and anti-CCP testing, primarily. 99mTc-
labeled anti-granulocyte joint scintigraphy is appropriate for the objective and
quantitative appraisal of disease activity.
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Introduction 
Rheumatoid arthritis (RA) is a chronic, immune-mediated, polyarticular inflammatory 
disorder, which afflicts approximately one per-cent of the adult population and leads to the 
gradual destruction of involved joints. RA is associated with a substantial deterioration in 
quality of life; moreover, it also reduces life expectancy. Therefore, early recognition, along 
with the prediction of subsequent prognosis and therapeutic efficacy are issues of utmost 
importance. In early RA (diagnosed 2 years before at the earliest), the literature keeps account 
of several prognostic factors, potentially useful for predicting the expected outcome of the 
disease.  Predictors, implicated with a higher probability of a poorer prognosis, and the 
evolution of destructive lesions include rheumatoid factor positivity [1], the presence of IgA-
type rheumatoid factors [2] and rheumatic nodules, female gender [3], and the abnormalities 
of the synovial fluid (leukocytosis, acidosis) [4]. New biological markers providing 
information on the destruction and renewal of articular cartilage have been identified. 
Cartilage oligomeric matrix protein (COMP), for example, has been suggested by TSENG et al 
as a potential diagnostic and prognostic marker, also suitable for monitoring therapeutic 
efficacy [5]. FUJIKAWA et al [6] reported similar findings. SYVERSEN et al presumed a weak 
correlation between joint destruction and the elevated serum level of collagen cross-linked C-
telopeptide (CTX-1), an established marker of bone resorption [7]. The serum levels of a 
variety of aggrecan molecules and their fragments have also been suggested as prognostic 
markers. ROUSSEAU et al detected a significant reduction of total aggrecan level, along with 
the presence of at least one specific subpopulation of aggrecan fragments [8]. Remarkable 
laboratory indices of prognostic value include anti-citrullinated protein/peptide antibodies 
(ACPA), and anti-mutant-citrullinated vimentin antibodies (anti-MCV). According to 
SYVERSEN et al, the presence of the latter is as reliable a predictor of subsequent articular 
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destruction as anti-CCP positivity [9]. Imaging studies are additional, important supplements 
to laboratory testing.  
According to clinical observations, neutrophil leukocytes predominate the cell 
population present in joints afflicted by active RA. Therefore, the accumulation of leukocytes 
may be regarded as an essential event in rheumatoid synovitis [10]. Although leukocyte 
infiltration into the joints of patients with early arthritis can be detected by scintigraphy, the 
value of this finding regarding the subsequent evolution of erosion is unknown [11]. 
Our study, conducted on patients with early rheumatoid arthritis (characterized by a 
disease duration shorter than a year), intended to ascertain the prognostic value of 
99m
Tc-
labeled leukocyte scintigraphy in predicting the eventual outcome of the disease process, 
especially the occurrence of erosions. 
Materials and methods 
Patients 
Twenty-five patients, who had been followed up at the Early Arthritis Center of ‘Kenézy 
Gyula’ Hospital were enrolled. The patient collection period started in December, 2008 and 
ended in December, 2009. All patients fulfilled the ACR 1987 criteria of RA [12] . By the end 
of the follow-up period of one year on average, clinical, and laboratory data were available on 
19 out of the 25 patients. 6 patient lost for follow up: 2 patients withdrew the informed 
consent, 3 patients refused the regular controls during the study because of traffic difficulties 
and 1 patient moved off from the city and became unreachable. 
Methods 
Upon inclusion, we reviewed clinical and laboratory data. An MRI of the hands was obtained 
to diagnose and quantify the synovitis and after that a planar joint scintigraphy was performed 
using Fab’ fragments of monoclonal, 99mTc-labeled anti-granulocyte antibodies (anti-NCA-90, 
sulesomab, LeukoScan
®
). MRI and scintigraphy were performed at an interval of two weeks 
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at the most. The clinical and laboratory patameters of the patients were followed up for a year 
on average. RA was managed with pharmacotherapy chosen by the rheumatologist 
responsible for the patient’s medical care, in view of clinical disease activity. MRI was 
repeated after a year on average. We correlated the severity of new erosions and of synovitis 
to baseline findings of MRI and scintigraphy. 
The used statistical methods were: the Kolmogorov–Smirnov test to investigate the normality 
of the data distribution, the Pearson’s correlation test for seeking the correlation between the 
clinical and scintigraphic data, the independent samples t-test to seek the relationship between 
anti-CCP positivity and the development of new erosions and synovitis and paired samples t 
test for evaluation of the changes in MRI scores (erosion and synivitis).  
The results were regarded to be significant if p value was <0,05. The study protocol was 
approved by the Institutional Review Board of University of Debrecen, Medical & Health 
Sciences Center; and an informed consent was obtained from all patients. 
MRI was performed using equipment specifically designed for imaging of the 
extremities (E-scan 0.2 T, Esaote Biomedica, Geneva, Italy) on recumbent patients.  Native, 
and gadolinium-enhanced (0.1 mmol/kg b. w. Gd-DTPA, Magnevist
®
, Schering, Berlin, 
Germany) coronal T1- and T2-weighted, STIR, as well as 3D T1-weighted images were 
obtained along with axial T1-weighted scans (Figure 2.). We evaluated the images according 
to the method described by KLARLUND et al in 2005 [13]. We appraised the erosions 
individually, in 14 localizations altogether (including the radial and ulnar epiphyses, all carpal 
bones, and the 2
nd
 through 5
th
 metacarpal heads), by absolute numbers, as well as by greatest 
diameters. Using the latter, the mean surface area of erosions in the studied regions were 
determined and then, aggregated. 
The synovitis score was evaluated semi-quantitatively, according to a four-grade scale 
(0 = no synovial thickening, 1 through 3 = mild/moderate/severe thickening) for each region 
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and then, individual scores were aggregated. The extent of synovitis was determined in the 
distal radioulnar, intercarpal, and in the second through fifth metacarpophalangeal joints (6 
localizations altogether) – thus, a maximal score of 18 could be achieved. This was increased 
further by the tenosynovitis score, which was “1” in the presence and “0” in the absence of 
detectable synovial inflammation.  
During the scintigraphy, 800 MBq 
99m
Tc LeukoScan (Immunomedics GmbH, Germany) 
was injected intravenously. The injected radioactivity was measured with a dose calibrator, 
and converted to counts/sec using the calibration factor measured for the camera-collimator 
system previously. Static images of the wrists and hands were acquired 4 h after the 
administration of the radiopharmaceutical. The images were acquired into 128*128 matrices 
over 5 minutes, using MB-9200 gamma camera (Gamma Move, Hungary) equipped with a 
LEOP collimator. The images were a) evaluated visually in a qualitative manner (for 
increased radiopharmaceutical uptake); and (b) the regional uptake of the radiopharmaceutical 
was calculated for the hands. Regions of interest (ROI-s) were drawn around the wrists and 
the hands (Figure 3.), and their uptake was expressed as a percentage of the injected dose 
(corrected for Tc decay). We aggregated regional radiopharmaceutical uptake measured in the 
joints  into a single uptake parameter (Cumulative Radiopharmaceutical-uptake Index-CRI). 
Results 
The essential clinical parameters of the study population are shown in Figure 1. At baseline, 
the mean age of patients was 53.5±11.9 years; the female-to-male ration was 15/4; and mean 
disease duration was 4.97±3.03 months. The clinical activity of synovitis was in the moderate 
range, as shown by the three-item activity index evaluating 28 joints (DAS28) of 3.83±1.19. 
Seven patients received methotrexate, one patient each was on hydroxychloroquine or 
sulfasalazine monotherapy; 5 underwent combination therapy with hydroxychloroquine and 
methotrexate. Additional combinations comprised methotrexate with sulfasalazine, 
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methotrexate with sulfasalazine and hydroxychloroquine, and methotrexate with 
hydroxychloroquine and leflunomide, in one patient each. Finally, two patients were treated 
with methotrexate, sulfasalazine, and leflunomide, as first-line combination therapy. Fifteen 
patients required transient steroid therapy over a period of 4.28±1.46 months on average. 
Eleven of then nineteen patients (58%) were rheumatoid factor-positive, whereas the 
proportion of anti-CCP (anti-cyclic citrullinated peptide) positive patients was 37% (7/19 
patients).  
Baseline MRI erosion score of the hands was 25.11±12.82; the initial synovitis score 
was 4.32±4.02, and the cumulative radiopharmaceutical uptake index (CRI) was 0.15±0.12. 
By the end of the follow-up period of 13.26 ±2.52 months, the MRI erosion and synovitis 
scores changed to 43.11±22.23 and 5.32±6.16, respectively (p=0,001 and p=0,015). 
We did not find statistically significant relationships between patient age, gender, and 
disease duration, as well as rheumatoid factor positivity, or the occurrence of erosions. 
DAS28 and initial synovitis scores, by contrast, were closely related (=0.622, 
p=0.042). The occurrence of new erosions was related both to the initial erosion score 
(=0.523, p=0.022), and to anti-CCP positivity (p=0.021). 
As shown in Figure 4. the cumulative radiopharmaceutical uptake index (CRI) 
measured by scintigraphy was correlated with anti-CCP positivity (p=0.048), as well as with 
baseline synovitis score (=0.518, p=0.023), but not with the extent of erosions that had 
evolved over the one-year-long follow-up period. 
 
Discussion 
 
The prevention of articular damage is the ultimate goal of the management of RA. The current 
therapeutic strategy is essentially determined by inflammatory activity, as this has been 
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reasonably related to subsequent erosiveness. A variety of disease activity indexes are in use 
for characterizing the intensity of arthritis. Disease Activity Score 28 (DAS28), which is the 
most widely used tool for this purpose [14], evaluates both objective components (number of 
swollen joints) and subjective elements (number of tender joints, subjective pain intensity 
assessed by the patient on a visual analogue scale), along with partially non-specific variables 
(ESR, C-reactive protein level). As a result, the reproducibility of articular indexes is at least 
questionable, considering the diverse pain perception thresholds of patients, or the non-
specific character of ESR.  
Many attempts have been made for the quantitation of the activity of arthritis by diagnostic 
imaging modalities, including radionuclide studies, some of which may prove adequate for 
determining the activity of RA. Having evaluated the extent of bone marrow edema with MRI 
of the hand, wrist, and feet in their study of 2-years duration, HETLAND et al consider this 
index the strongest, independent predicting factor of radiological progression [15]. 
PALOSAARI et al found a close relationship between bone marrow edema and subsequent 
articular erosions in their 2-year study [16]. OSTGENDORF et al studied the diagnostic efficacy 
of duplex ultrasound, positron emission tomography (PET), and mini-arthroscopy and found 
this combination useful for the early detection of pathomorphological abnormalities as well as 
for the prediction of prognosis [17]. 
VAN DER LAKEN found that the PET imaging of macrophages, undertaken after the 
[11C](R)-PK11195-labeling of their benzodiazepine receptors, offers non-invasive means 
both for the detection of incipient synovitis and for the subsequent monitoring of its activity 
[18]. Studying 13 RA patients with 
99m
Tc-MDP joint scintigraphy, MÖTTÖNEN et al 
demonstrated a correlation between high scintigraphic activity and subsequent erosiveness. 
Their findings also suggest that erosions do not evolve in scintigraphically inactive joints 
19].  
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DE BOIS et al had performed 
99m
Tc-IgG joint scintigraphy in 30 patients with early 
rheumatoid arthritis and found, after one-year of follow-up, that this form of radionuclide 
imaging might prove useful for the prediction of joint destruction [20]. TAKALO et al reported 
similar results with of 
99m
Tc-nanokolloid joint scintigraphy [21]. Using 
99m
Tc-HMPAO-
leukocyte scintigraphy, our work group showed a relationship between the magnitude of 
articular leukocyte infiltration and the number of swollen joints [14]. 
No studies have been conducted to date to clarify the relationship between the extent of 
leukocyte infiltration and disease activity, or erosiveness. As suggested by the relationship 
between CRI (calculated radionuclide uptake index) of the hands and anti-CCP positivity, as 
well as the MRI synovitis score, 
99m
Tc-labeled anti-granulocyte joint scintigraphy is 
appropriate for the objective and quantitative appraisal of disease activity, primarily. 
Nevertheless, 
99m
Tc-labeled anti-granulocyte scintigraphy should be performed when 
access to MRI is limited, non-existent, or the waiting list for this test is long. Moreover, the 
cost of 
99m
Tc-labeled anti-granulocyte scintigraphy is significantly lower than that of MRI, 
and being a ubiquitously available (in any radioisotope diagnostic laboratory equipped with a 
gamma camera), rapid, and relatively straightforward test, it is a realistic alternative to MRI in 
cases where the objective appraisal of the activity of arthritis is important. High scintigraphic 
activity detected over the hands suggests a substantial leukocyte infiltration, which might 
require the early initiation of aggressive therapy. 
Study limitations: the relatively low patient number, and the lack of a uniform treatment 
algorhytm may be considered a potential flaw of this study. 
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Figure legends 
Figure 1.  
Essential clinical data of the study population  
Figure 2. 
3DT1-weighted MRI images of the region from the radiocarpal to the MCP joints of the same 
patient. Left: No erosions are visible on this baseline scan. Right: On this image obtained 13 
months later, erosions are depicted on the lateral-radial surface of the distal radioulnar joint.  
Figure 3. 
99mTc anti-granulocyte scintiscan of the hands, with superimposed ROIs: the involvement of 
the left wrist and of the second MCP joint of the right hand are visible. 
Figure 4. 
The relationship between the cumulative index of radioisotope uptake and baseline synovitis 
score. 
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